Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 3/20 | 0.42 |
| ▸ | F11 | P03951 | 4/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17014697 | 0.87 | ALDH1A1 (0.48) | ALDH1A1HPGDXDHF11ACE2 | |
| SCHEMBL3055745 | 0.83 | CA1 (0.42) | ALDH1A1HPGDXDH | |
| SCHEMBL3908449 | 0.77 | ACE2 (0.51) | ALDH1A1HPGDXDHACE2 | |
| SCHEMBL30211966 | 0.77 | ACE2 (0.51) | ALDH1A1HPGDXDHACE2 | |
| SCHEMBL1872491 | 0.76 | XDH (0.60) | ALDH1A1HPGDXDHF11 | |
| SCHEMBL16897459 | 0.75 | MAOB (0.42) | ALDH1A1HPGD | |
| SCHEMBL29472005 | 0.75 | ALDH1A1 (0.59) | ALDH1A1HPGDXDHMRGPRX4 | |
| SCHEMBL4844022 | 0.75 | ALDH1A1 (0.59) | ALDH1A1HPGDXDHMRGPRX4 | |
| SCHEMBL996704 | 0.74 | MRGPRX4 (0.56) | ALDH1A1HPGDMRGPRX4 | |
| SCHEMBL108705 | 0.74 | ALDH1A1 (0.48) | ALDH1A1HPGDXDHMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | ALDH1A1 137/4885HPGD 178/4885XDH 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.